Compare ADVB & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADVB | BOLT |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 7.1M |
| IPO Year | 2023 | 2021 |
| Metric | ADVB | BOLT |
|---|---|---|
| Price | $7.09 | $3.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $29.00 |
| AVG Volume (30 Days) | ★ 42.8K | 31.2K |
| Earning Date | 11-18-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.21 | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,525.07 |
| P/E Ratio | $1.21 | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.19 | $3.10 |
| 52 Week High | $24.23 | $7.20 |
| Indicator | ADVB | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 47.24 |
| Support Level | $6.17 | $3.13 |
| Resistance Level | $6.44 | $4.34 |
| Average True Range (ATR) | 0.51 | 0.32 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 0.47 | 40.48 |
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.